Ileal Ecology After Pouch-Anal Anastomosis or Ileostomy

Nasmyth, D. G.; Godwin, P. G. R.; Dixon, M. F.; Williams, Norman S.; Johnston, D.

doi:10.1016/s0016-5085(89)80082-4

Cited by 119 publications

(27 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Samples obtained from fasted children gave an estimate of 0.1 mM in the proximal small intestine (39). Finally, concentrations of 0.1-16 mM butyrate were measured in the distal small intestine sampled via ileostomies (40).…”

Section: Discussionmentioning

confidence: 99%

Macrophage inflammatory protein-2: Chromosomal regulation in rat small intestinal epithelial cells

Ohno

Lee

Fusunyan

et al. 1997

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Nonpathogenic, resident bacteria participate in the pathogenesis of inf lammation in the small intestine, but the molecular messages produced by such bacteria are unknown. Inf lammatory responses involve the recruitment of specific leukocyte subsets. We, therefore, hypothesized that butyrate, a normal bacterial metabolite, may modulate chemokine secretion by epithelial cells, by amplifying their response to proinf lammatory signals. We studied the expression of the chemokine, macrophage inf lammatory protein-2 (MIP-2) by the rat small intestinal epithelial cell line, IEC-6. Cells were stimulated with lipopolysaccharide or with interleukin 1␤ (IL-1␤) and incubated with sodium butyrate. Acetylation of histones was examined in Triton X acetic acid-urea gels by PAGE.

show abstract

Section: Discussionmentioning

confidence: 99%

Macrophage inflammatory protein-2: Chromosomal regulation in rat small intestinal epithelial cells

Ohno

Lee

Fusunyan

et al. 1997

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…[1][2][3] Most episodes of pouchitis are single attacks usually responding to metronidazole or antibiotic combination therapy. 4 The good response to antibiotic therapy directed against anaerobic bacteria suggests a role for the bacterial flora in the pouch.…”

Section: Introductionmentioning

confidence: 99%

Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora

Kuisma

Mentula

Järvinen

et al. 2003

Aliment Pharmacol Ther

255

121

View full text Add to dashboard Cite

SUMMARYBackground: Preliminary trials of probiotics in preventing recurrent chronic pouchitis have been encouraging. Aim: To investigate the efficacy of Lactobacillus GG supplementation as primary therapy for ileal pouch inflammation, and its effect on the microbial flora. Methods: Twenty patients, with a previous history of pouchitis and endoscopic inflammation, were recruited for a prospective, randomized, double-blind, placebocontrolled trial of Lactobacillus GG supplementation (10 LGG, 10 placebo) in two gelatine capsules [(0.5-1) · 10 10 colony-forming units/capsule] b.d. for 3 months. Quantitative bacterial culture of fresh faecal samples and biopsies taken from the pouch and afferent limb was performed before and after supplementation.

show abstract

“…It may be that the coating action of the foam functioned as a protective barrier in the pouch, shielding the mucosa from the effects of faecal stasis, or that the placebo could have acted simply as a washing agent to clear stool and bacteria from the pouch. 18 The treatment period in this study was 3 weeks, which may have been too short a time to demonstrate ef®cacy of the study medication. In an open label trial lasting 45 days, bismuth carbomer enemas appeared effective for chronic treatment-resistant pouchitis.…”

Section: Discussionmentioning

confidence: 99%

Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double‐blind, placebo‐controlled trial

Tremaine

Sandborn

Wolff

et al. 1997

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background:Bismuth carbomer liquid enemas are equivalent to mesalamine enemas for active distal ulcerative colitis.Aims:In this study, the efficacy and safety of bismuth carbomer foam enemas for active chronic pouchitis was determined in a placebo‐controlled trial.Patients:Forty adult patients with active chronic pouchitis were randomly assigned into either concurrent therapy for pouchitis or no concurrent therapy. Topical corticosteroids and mesalamine were withdrawn prior to the study.Methods:Patients received either bismuth carbomer (270 mg elemental bismuth) (n=20) or placebo (n=20) foam enemas for 3 weeks. Clinical assessment was performed at baseline and at 3 weeks using the pouchitis disease activity index score which incorporates symptoms, endoscopy and histology. Serum bismuth concentrations were determined by atomic absorption spectrophotometry.Results:At 3 weeks nine of 20 patients (45%) in both the bismuth and placebo groups had improved. Ten patients discontinued prematurely because of worse diarrhoea (three in each group) or abdominal cramping after enema use (one from the bismuth group and three from the placebo group). No other side‐effects were noted. Serum bismuth concentrations were negligible in all patients.Conclusions:Bismuth carbomer foam enemas (270 mg bismuth) nightly for 3 weeks are safe but not efficacious for active chronic pouchitis.

show abstract

Ileal Ecology After Pouch-Anal Anastomosis or Ileostomy

Cited by 119 publications

References 17 publications

Macrophage inflammatory protein-2: Chromosomal regulation in rat small intestinal epithelial cells

Macrophage inflammatory protein-2: Chromosomal regulation in rat small intestinal epithelial cells

Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora

Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double‐blind, placebo‐controlled trial

Contact Info

Product

Resources

About